ICER Releases Evidence Report on Acute Treatments for Migraine

-- Lasmiditan, rimegepant, and ubrogepant all perform better than placebo, but evidence is not adequate to distinguish among them; generic triptans remain the most effective option for acute treatment for most patients requiring prescription medications --

-- At prices anticipated by analysts, all three drugs would exceed common thresholds for cost-effectiveness --

Read More

ICER Issues Final Report and Policy Recommendations on JAK Inhibitors for Rheumatoid Arthritis

-- Despite upadacitinib reaching common thresholds for cost-effectiveness when compared to adalimumab, the independent appraisal committee’s votes on upadacitinib’s long-term economic value were split between “low” and “intermediate” due to concerns about the generalizability of the clinical data to patients in the real world --

-- During the policy roundtable, experts expressed frustration over the dysfunctional rebate structure that distorts coverage and access to therapies indicated to treat several inflammatory diseases --

Read More

ICER Issues Final Report and Policy Recommendations for Add-on Therapies to Treat Type 2 Diabetes

-- Oral GLP-1 semaglutide achieves commonly cited thresholds for cost-effectiveness but is less cost-effective than SGLT-2 competitor empagliflozin --

-- Independent appraisal committee votes that oral semaglutide provides a superior net health benefit over background therapy alone, achieves intermediate long-term value for money, and may be an attractive alternative for patients who would prefer an oral treatment; however, the large potential short-term budget impact associated with treating even a small percentage of eligible US patients leads ICER to issue an Access and Affordability Alert --

Read More